Assessing the ED Stroke Patient for Disability - What Are the Pitfalls and How to Avoid Them?

December 2, 2020

The NIH Stroke Scale is beneficial when used correctly but is has its limitations. Relying entirely on the NIHSS will miss significant disability in a number of patients. Acute stroke care demands more than just an NIHSS assessment.

0 Comments

Tweet Share

What Lessons Have You Learned About Endovascular Therapy in COVID Patients and What Should We All Know?

December 2, 2020

Acute interventional management during the COVID pandemic requires a change of focus and practice. Challenges abound and danger exists at every decision point.

0 Comments

Tweet Share

Controversies in Prehospital Medicine: Choosing the Destination Medical Center for Stroke Patients

December 2, 2020

Once a stroke is suspected in the field, it stands to reason that the destination matters for the patient. But how much does it matter and where should patients be taken? Data meets politics in this compelling podcast.

0 Comments

Tweet Share

When Might You Use Heparin in the NeuroICU for a Stroke Patient?

December 2, 2020

Heparin in stroke remains controversial. Understanding the history and data and essential to mastering stroke care.

0 Comments

Tweet Share

Are the NNT and NNH for tPA Useful or Misleading in Acute Stroke Care?

December 2, 2020

Stroke treatment data are hard to interpret and can be misleading. A lot of misinformation has made its way into the literature and has confounded acute stroke care. Understanding NNT and NNH can help clinicians understand risks and benefits in a meaningful way.

0 Comments

Tweet Share

RSS

First Previous 1 2 3 4 5 6 7 8 9 10 Next

Dec 4

What Was Missing From the NINDS Trial?

Brian Gibler posted on 12/4/2020

Moderator: Jordan Bonomo, MD, FCCM, FNCS
Other Participants: Opeolu Adeoye, MD, MS FACEP, FAHA

The NINDS trial was the seminal study of IV-tPA in the treatment of acute stroke. Yet controversy still exists around the trial methodology and the interpretation of the data. Was anything missing from NINDS? Does it still resonate nearly 25 years later?

Dr. Opeolu (Ope) Adeoye sits down with Dr. Jordan Bonomo and shares his immense expertise in clinical trialing. As a researcher carrying over $30M in research funding, Dr. Adeoye is an internationally recognized stroke trialist and methodologist. In this podcast, he talks about the challenges of the NINDS trial, what was really well done and what could have been different. “Time critical diagnosis” is the term he wields in this exciting and thought provoking podcast.